Background While cannabidiol (CBD) is widely used globally as a therapeutic agent, sex as a biological variable remains underexplored in determining its metabolism and overall pharmacokinetic patterns. The present study systematically evaluated sex differences in the pharmacokinetics of CBD and its major metabolites, 7-hydroxy-CBD (7-OH-CBD) and 7-carboxy-CBD (7-COOH-CBD), in a mouse model. Methods Male and female C57BL/6J mice received an intraperitoneal dose of CBD (120 mg/kg) and plasma concentrations of CBD and its metabolites were quantified by UPLC–MS/MS. Pharmacokinetic parameters were derived using non-compartmental analysis and compared between sexes. Results Females exhibited significantly higher early exposure to CBD, with a ~ 1.5-fold higher <InlineEquation ID="IEq1"> <EquationSource Format="TEX">\(\:{C}_{\text{m}\text{a}\text{x}}\:\)</EquationSource> </InlineEquation>than male mice (p = 0.03). The apparent clearance (CL/F) and ultimate total systemic exposure<InlineEquation ID="IEq2"> <EquationSource Format="TEX">\(\:{\:AUC}_{0-\text{I}\text{N}\text{F}}\)</EquationSource> </InlineEquation> were comparable between sexes. In contrast, male mice demonstrated a markedly larger apparent volume of distribution (Vz/F; ~2.2-fold increase, p = 0.02) and consequently a longer terminal half-life (t1/2; ~2.2-fold increase, p = 0.04), indicating greater tissue sequestration. Both metabolites were significantly higher in female vs. male mice (7-OH-CBD <InlineEquation ID="IEq3"> <EquationSource Format="TEX">\(\:{C}_{\text{m}\text{a}\text{x}}\:\)</EquationSource> </InlineEquation>~1.6-fold, p = 0.03; 7-COOH-CBD <InlineEquation ID="IEq4"> <EquationSource Format="TEX">\(\:{C}_{\text{m}\text{a}\text{x}}\)</EquationSource> </InlineEquation> ~1.7-fold, p = 0.03). The <InlineEquation ID="IEq5"> <EquationSource Format="TEX">\(\:{AUC}_{0-\text{I}\text{N}\text{F}}\)</EquationSource> </InlineEquation> tended to be higher for 7-OH-CBD in female mice but was not significant (~ 1.4-fold, p = 0.11), whereas the 7-COOH-CBD <InlineEquation ID="IEq6"> <EquationSource Format="TEX">\(\:{AUC}_{0-24\text{h}}\)</EquationSource> </InlineEquation> was significantly greater in females (~ 1.8-fold, p = 0.04). Male mice displayed substantially longer terminal half-lives for both metabolites (7-OH-CBD ~2.4-fold, p = 0.0051; 7-COOH-CBD ~3.7-fold, p = 0.02). Conclusions These results demonstrate that sex is a critical determinant of CBD pharmacokinetics and highlight the need for sex-informed dosing considerations in both preclinical study design and potentially for future clinical applications of CBD.

Sex differences in the disposition of cannabidiol and its metabolites in mice

期刊论文
出版模式：

开放获取
发表日期：

2026年4月2日

查看全文

Margaret E. Olawale,
Mrunmayi D. Lad,
Mmesoma C. Anyachebelu,
Shaman Luo,
Philip Lazarus

摘要

Background

While cannabidiol (CBD) is widely used globally as a therapeutic agent, sex as a biological variable remains underexplored in determining its metabolism and overall pharmacokinetic patterns. The present study systematically evaluated sex differences in the pharmacokinetics of CBD and its major metabolites, 7-hydroxy-CBD (7-OH-CBD) and 7-carboxy-CBD (7-COOH-CBD), in a mouse model.

Methods

Male and female C57BL/6J mice received an intraperitoneal dose of CBD (120 mg/kg) and plasma concentrations of CBD and its metabolites were quantified by UPLC–MS/MS. Pharmacokinetic parameters were derived using non-compartmental analysis and compared between sexes.

Results

Females exhibited significantly higher early exposure to CBD, with a ~ 1.5-fold higher \(\:{C}_{\text{m}\text{a}\text{x}}\:\) than male mice (p = 0.03). The apparent clearance (CL/F) and ultimate total systemic exposure \(\:{\:AUC}_{0-\text{I}\text{N}\text{F}}\) were comparable between sexes. In contrast, male mice demonstrated a markedly larger apparent volume of distribution (Vz/F; ~2.2-fold increase, p = 0.02) and consequently a longer terminal half-life (t_1/2; ~2.2-fold increase, p = 0.04), indicating greater tissue sequestration. Both metabolites were significantly higher in female vs. male mice (7-OH-CBD \(\:{C}_{\text{m}\text{a}\text{x}}\:\) ~1.6-fold, p = 0.03; 7-COOH-CBD \(\:{C}_{\text{m}\text{a}\text{x}}\) ~1.7-fold, p = 0.03). The \(\:{AUC}_{0-\text{I}\text{N}\text{F}}\) tended to be higher for 7-OH-CBD in female mice but was not significant (~ 1.4-fold, p = 0.11), whereas the 7-COOH-CBD \(\:{AUC}_{0-24\text{h}}\) was significantly greater in females (~ 1.8-fold, p = 0.04). Male mice displayed substantially longer terminal half-lives for both metabolites (7-OH-CBD ~2.4-fold, p = 0.0051; 7-COOH-CBD ~3.7-fold, p = 0.02).

Conclusions

These results demonstrate that sex is a critical determinant of CBD pharmacokinetics and highlight the need for sex-informed dosing considerations in both preclinical study design and potentially for future clinical applications of CBD.